BridgeBio Pharma Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: BridgeBio Pharma Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: Palo Alto
Headquarters state / province: California
Headquarters country: United States
Fiscal year end: December
Ticker symbol: BBIO
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001743881

Board of directors

Follow this board

Ali J. Satvat · Director
Since 2023
Andrea Ellis · Director
Since 2023
Andrew Lo · Director
Since 2023
Charles J. Homcy · Director
Since 2023
Douglas A. Dachille · Director
Since 2023
Eric Aguiar · Director
Since 2023
Frank Mccormick · Director
Since 2023
Fred Hassan · Director Overboarded
Since 2023
Hannah Valantine · Director
Since 2023
James C. Momtazee · Director
Since 2023
Jennifer E. Cook · Director
Since 2023
Neil Kumar · Director · Chief Executive Officer
Since 2023
Randal W. Scott · Director
Since 2023
Richard H. Scheller · Director
Since 2023
Ronald J. Daniels · Director
Since 2023

Chief executives

Neil Kumar · CEO and President

Dates unknown

Director election results

Annual meeting of June 22, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

13 of this board's directors also sit on 18 other boards. 14 are in the same sector.

Shared director Other board Same sector +2 more in the list below

Maze Therapeutics Inc. Same sector
via Charles J. Homcy, Neil Kumar and Richard H. Scheller
BridgeBio Oncology Therapeutics Inc. Same sector
via Frank Mccormick and Neil Kumar
AbCellera Biologics Inc. Same sector
via Andrew Lo
Alector Inc. Same sector
via Richard H. Scheller
Biomea Fusion Inc. Same sector
via Eric Aguiar
CareDx Inc. Same sector
via Hannah Valantine
Cocrystal Pharma Inc. Same sector
via Fred Hassan
Coherus Oncology Inc. Same sector
via Ali J. Satvat
Denali Therapeutics Inc. Same sector
via Jennifer E. Cook
Equitable Holdings Inc.
via Douglas A. Dachille
EyePoint Inc.
via Fred Hassan
Freenome Inc. Same sector
via Randal W. Scott
Jazz Pharmaceuticals plc Same sector
via Jennifer E. Cook
Pacific Biosciences of California Inc.
via Hannah Valantine
Precigen Inc. Same sector
via Fred Hassan
Recursion Pharmaceuticals Inc. Same sector
via Fred Hassan
Roivant Sciences Ltd. Same sector
via James C. Momtazee
The PNC Financial Services Group Inc.
via Douglas A. Dachille

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $96,322,125; 141 sales by 8 insiders

Date	Insider	Transaction	Shares	Price	Value
Oct 30, 2026	Apuli Maricel Officer (Chief Accounting Officer)	Open-market sale	−2,000	$72.85	$145,700
Sep 17, 2026	Neil Kumar Director, Officer (Chief Executive Officer)	Open-market sale	−8,721	$69.01	$601,836
Sep 17, 2026	Neil Kumar Director, Officer (Chief Executive Officer)	Open-market sale	−1,279	$69.57	$88,980
Aug 19, 2026	Neil Kumar Director, Officer (Chief Executive Officer)	Open-market sale	−8,100	$83.86	$679,266
Aug 19, 2026	Neil Kumar Director, Officer (Chief Executive Officer)	Open-market sale	−1,800	$84.69	$152,442
Aug 19, 2026	Neil Kumar Director, Officer (Chief Executive Officer)	Open-market sale	−100	$85.65	$8,565
Aug 18, 2026	Neil Kumar Director, Officer (Chief Executive Officer)	Open-market sale	−1,900	$81.15	$154,185
Aug 18, 2026	Neil Kumar Director, Officer (Chief Executive Officer)	Open-market sale	−17,279	$82.21	$1,420,507
Aug 18, 2026	Neil Kumar Director, Officer (Chief Executive Officer)	Open-market sale	−14,602	$82.99	$1,211,820
Aug 18, 2026	Neil Kumar Director, Officer (Chief Executive Officer)	Open-market sale	−1,199	$83.77	$100,440
Aug 16, 2026	Apuli Maricel Officer (Chief Accounting Officer)	Shares withheld for tax	−4,714	$79.86	$376,460
Aug 16, 2026	Neil Kumar Director, Officer (Chief Executive Officer)	Option exercise	+33,544	—	—
Aug 16, 2026	Trimarchi Thomas Officer (President and CFO)	Shares withheld for tax	−22,781	$79.86	$1,819,291
Aug 16, 2026	Neil Kumar Director, Officer (Chief Executive Officer)	Option exercise	+19,599	—	—
Aug 16, 2026	Neil Kumar Director, Officer (Chief Executive Officer)	Option exercise	+11,554	—	—

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about BridgeBio Pharma Inc.

Who is the CEO of BridgeBio Pharma Inc.?

Neil Kumar is BridgeBio Pharma Inc.'s CEO and President.

How many directors are on BridgeBio Pharma Inc.'s board?

BridgeBio Pharma Inc.'s board has 15 directors: Ali J. Satvat, Andrea Ellis, Andrew Lo, Charles J. Homcy, Douglas A. Dachille, Eric Aguiar, Frank Mccormick, Fred Hassan, Hannah Valantine, James C. Momtazee and 5 others.

Are BridgeBio Pharma Inc. insiders buying or selling shares?

Over the last 12 months, BridgeBio Pharma Inc. insiders made no open-market purchases and sold $96.3 million of shares in 141 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is BridgeBio Pharma Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="bridgebio-pharma-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.